Dachaigh › Obesity › North Carolina › Wilmington
Sgrùdaidhean clionaigeach Obesity ann an Wilmington, NC
Tha 15 sgrùdaidhean airson Obesity a’ lorg phàirtichean aig làraichean ann agus timcheall air Wilmington (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
A’ fastadhÌre 2
- Accellacare - Tradd Court - Wilmington /ID# 282200, Wilmington
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
A’ fastadhÌre 3
- Accellacare - Wilmington, Wilmington
- Jeffrey Coleman, OD, Wilmington
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
A’ fastadhÌre 2
- TMA Headlands, Wilmington
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
A’ fastadhÌre 3
- Accellacare and KDCILM, LLC, Wilmington
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
A’ fastadhÌre 3
- Accellacare and KDCILM, LLC, Wilmington
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A’ fastadhÌre 3
- Accellacare - Wilmington - 1917 Tradd Court, Wilmington
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
A’ fastadhÌre 3
- Trial Management Associates - Wilmington - Floral Parkway, Wilmington
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
A’ fastadhÌre 3
- Accellacare of Wilmington, Wilmington
A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
A’ fastadhÌre 3
- KDCILM, LLC & Accellacare US, Inc., Wilmington
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
A’ fastadhÌre 3
- Accellacare Research of Wilmington, Wilmington
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
A’ fastadhÌre 3
- Accellacare Wilmington, Wilmington
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
A’ fastadhÌre 3
- ACCOMPLISH-1 Research Site, Wilmington
A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
A’ fastadhÌre 2
- Accellacare of Wilmington, Wilmington
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
A’ fastadhÌre 3
- Accellacare and KDCILM, LLC, Wilmington
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
A’ fastadhÌre 1
- Accellacare, Wilmington
Sgrùdaidhean Obesity ann am bailtean eile
- Houston, TX43 sgrùdaidhean
- Chicago, IL41 sgrùdaidhean
- New York City, NY40 sgrùdaidhean
- San Antonio, TX40 sgrùdaidhean
- Washington, DC33 sgrùdaidhean
- Orlando, FL32 sgrùdaidhean
- Dallas, TX30 sgrùdaidhean
- Boston, MA28 sgrùdaidhean
- Las Vegas, NV27 sgrùdaidhean
- Miami, FL27 sgrùdaidhean
- Baltimore, MD26 sgrùdaidhean
- Jacksonville, FL25 sgrùdaidhean
Sgrùdaidhean eile ann an Wilmington
- Ro-throm11 sgrùdadh
- Diabaitis Seòrsa 28 sgrùdaidhean
- Fàilligeadh a' Chridhe6 sgrùdaidhean
- Colitis Ulcerative4 sgrùdaidhean
- Cholesterol3 sgrùdaidhean
- Galarachd Cardiovasculach3 sgrùdaidhean
- Brùthadh-fala àrd3 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.